Abstract
Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies
Journal of clinical oncology, Vol.39(15_suppl), pp.TPS3161-TPS3161
05/20/2021
DOI: 10.1200/JCO.2021.39.15_suppl.TPS3161
Abstract
TPS3161
Background: The p53 pathway has been implicated in antitumor immunity, including antigen presentation and T-cell proliferation. Loss of p53 function can increase resistance to immunotherapy across many tumor types. Eprenetapopt (eprenet) is a small molecule that stabilizes the folded structure of p53, resulting in activation of mutant p53 and stabilization of wild-type (WT) p53. It also targets the cellular redox homeostasis, resulting in induction of apoptosis in tumor cells. In vivo, mice carrying supernumerary copies of the TP53 gene harbor a pro-inflammatory tumor microenvironment, an effect recapitulated in TP53 normal-copy mice treated with eprenetapopt. Combining eprenetapopt and anti-PD1 or anti-CTLA4 therapy resulted in enhanced tumor growth inhibition and improved survival in TP53 WT mice inoculated with B16 melanoma and MC38 colon adenocarcinoma cells . Based on these results, we hypothesized that eprenet-induced p53 stabilization may augment response to immunotherapy. To test this hypothesis, we are conducting a phase 1b/2 study of eprenet in combination with pembrolizumab (eprenet+pembro) in pts with solid tumors. Methods: The primary objectives are to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) and to assess the safety and tolerability of eprenet+pembro in pts with advanced solid tumors. The secondary objectives are to estimate the anti-tumor activity and to describe the pharmacokinetics of the combination. Exploratory objectives include assessing predictive and pharmacodynamic markers of response. The study includes a safety lead-in with a 3+3 dose de-escalation design for pts with advanced solid tumors with known tumor TP53 mutation status ( TP53 WT is acceptable) (max 18 pts), followed by expansion cohorts in pts with NSCLC, gastric/GEJ and urothelial cancer (max 100 pts). In expansion, pts with urothelial and gastric cancers must be naïve to anti-PD-1/ L1 therapy. Eprenet is given IV once daily on Days 1–4 while pembro is administered on Day 3 of each 21-day cycle. The RP2D of eprenet+pembro is considered the dose at which ≤ 1 of 6 pts in a cohort has a dose-limiting toxicity (DLT). Primary endpoints are occurrence of DLTs, adverse events (AEs) and serious AEs with eprenet+pembro. Key secondary endpoints are best objective response, progression free survival and overall survival. Exploratory endpoints include gene mutations by next generation sequencing (including TP53), mRNA expression, multiplex immunohistochemistry and transcriptomics, multiplex flow cytometry on peripheral blood mononuclear cells and cytokines in serum. Continuous monitoring of toxicity will be conducted. The trial opened in May 2020 and is actively enrolling patients. Clinical trial information: NCT04383938.
Details
- Title: Subtitle
- Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies
- Creators
- Ecaterina Elena Dumbrava - The University of Texas MD Anderson Cancer CenterAmit Mahipal - Mayo Clinic Rochester, MNXin Gao - Dana-Farber Cancer InstituteGeoffrey Shapiro - Dana-Farber Cancer InstituteJason S. Starr - University of Florida Health Science CenterParminder Singh - Mayo Clinic HospitalMuhammad Furqan - University of IowaAfzal Ahrorov - The University of Texas MD Anderson Cancer CenterDenice Hickman - Aprea Therapeutics, Boston, MA;Amy Gubits - Aprea Therapeutics, Boston, MA;Eyal C. Attar - Agios PharmaceuticalsMark M. Awad - Massachusetts General HospitalSatya Das - Vanderbilt University Medical CenterHaeseong Park - Washington University in St. Louis
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.39(15_suppl), pp.TPS3161-TPS3161
- DOI
- 10.1200/JCO.2021.39.15_suppl.TPS3161
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- name: Aprea Therapeutics
- Language
- English
- Date published
- 05/20/2021
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362338802771
Metrics
12 Record Views